Welcome to our dedicated page for Durect news (Ticker: DRRX), a resource for investors and traders seeking the latest updates and insights on Durect stock.
DURECT Corporation (Nasdaq: DRRX) is a specialized biopharmaceutical company focused on the research, development, and manufacturing of innovative pharmaceutical products. With expertise in drug discovery, delivery, and development, DURECT dedicates its efforts to creating therapies aimed at pain management, acute organ injury, and metabolic diseases. Their proprietary technologies, including oral, transdermal, and injectable depot delivery systems, enhance clinical and commercial attributes such as abuse deterrence, convenience, adherence, efficacy, and safety for both small molecule and biologic drugs.
One of DURECT’s key assets is larsucosterol, an epigenetic modulator currently in Phase 3 clinical trials for the treatment of severe alcohol-associated hepatitis (AH). This promising candidate has received both Fast Track and Breakthrough Therapy designations from the FDA. The company's Phase 2b AHFIRM trial demonstrated significant potential in reducing mortality among AH patients, paving the way for further research and development.
Another noteworthy product is POSIMIR®, an FDA-approved non-opioid analgesic for post-surgical pain management, which utilizes DURECT’s SABER® platform technology. It is exclusively licensed to Innocoll Pharmaceuticals for distribution in the United States.
DURECT also markets ALZET® osmotic pumps, widely used in preclinical research for continuous drug delivery in laboratory animals. A collaboration with Charles River Laboratories aims to further expand the reach of this product line within the pharmaceutical and academic sectors.
Financially, DURECT continues to advance its pipeline with strategic capital management, ensuring the sustainability of its operations while actively seeking regulatory approvals for its drug candidates. Their latest developments include quarterly financial reports, conference calls with stakeholders, and presentations at major medical conferences, showcasing their commitment to transparency and progress.
For more information, visit www.durect.com and follow the company on X (formerly Twitter) at https://x.com/DURECTCorp.
DURECT Corporation (Nasdaq: DRRX) will report its Q3 2021 financial results on November 2, 2021, at 4:30 PM ET. A conference call will follow to discuss these results. The company is advancing its lead drug candidate, DUR-928, aimed at treating alcohol-associated hepatitis, currently in a Phase 2b clinical trial. The FDA has granted it Fast Track Designation. Additionally, DURECT's POSIMIR has received FDA approval. Investors should watch for performance metrics and further developments on the clinical trials during the upcoming call.
DURECT Corporation (Nasdaq: DRRX) announced participation in a fireside chat at the H.C. Wainwright 5th Annual NASH Investor Conference on October 12, 2021, from 2:30 PM to 3:00 PM EST. Key executives including CEO James E. Brown and CFO Michael H. Arenberg will present. The company's lead drug candidate, DUR-928, is in Phase 2b clinical trials for alcohol-associated hepatitis and has received FDA Fast Track Designation. POSIMIR, a non-opioid analgesic, is FDA-approved. Management will also hold virtual one-on-one meetings during the event.
DURECT Corporation (Nasdaq: DRRX) announced participation in a fireside chat at the Cantor Fitzgerald Global Healthcare Conference 2021, scheduled for September 28, 2021, from 2:40 P.M. to 3:10 P.M. EST. The discussion will feature key executives, including CEO James E. Brown and CFO Michael H. Arenberg. Investors can access the webcast through DURECT's website. The company focuses on developing therapies for acute organ injury and chronic liver diseases, with its lead candidate, DUR-928, currently in a Phase 2b trial for alcohol-associated hepatitis.
DURECT Corporation (Nasdaq: DRRX) announced participation in a fireside chat at Oppenheimer's Fall Healthcare Life Sciences & MedTech Summit on September 22, 2021. Key executives, including CEO James E. Brown and CFO Michael H. Arenberg, will engage in discussions highlighting the company’s strategies and clinical developments. The presentation will focus on DURECT's lead drug candidate, DUR-928, currently in a Phase 2b trial for alcohol-associated hepatitis, and its FDA-approved product, POSIMIR. The webcast can be accessed through DURECT's website, promoting transparency and investor engagement.
DURECT Corporation (Nasdaq: DRRX) announced participation in a fireside chat at the H.C. Wainwright 23rd Annual Global Investment Conference on September 13, 2021. Management, including CEO James E. Brown and CFO Michael H. Arenberg, will discuss the company’s progress and strategies. A recording will be available on-demand starting at 7:00 A.M. ET on the same day. DURECT is advancing its lead drug candidate, DUR-928, for alcohol-associated hepatitis, with FDA Fast Track Designation, while its POSIMIR product is FDA-approved.
DURECT Corporation (Nasdaq: DRRX) reported Q2 2021 total revenues of $2.3 million with a net loss of $9.1 million, down from $24.5 million revenue and a net income of $14.3 million in Q2 2020.
They expanded U.S. clinical sites for the Phase 2b AHFIRM study of DUR-928 for severe alcohol-associated hepatitis. Future sites are planned in the UK, Europe, and Australia. DUR-928 shows promise in treating liver conditions, with Fast Track Designation from the FDA. Additionally, POSIMIR received FDA approval for post-surgical analgesia. Cash and investments rose to $88.6 million as of June 30, 2021.
DURECT Corporation (Nasdaq: DRRX) will disclose its second-quarter 2021 financial results and host a conference call on July 29, 2021, at 4:30 PM ET. The company is developing DUR-928, which aims to treat alcohol-associated hepatitis and has received Fast Track Designation from the FDA. Currently, they are conducting a Phase 2b clinical trial named AHFIRM. Additionally, the company's POSIMIR product has gained FDA approval. DURECT also cautions about risks related to clinical trials and commercialization.
DURECT Corporation (Nasdaq: DRRX) will present at the Epigenetic Therapeutic Targets Summit on July 15, 2021, discussing its lead drug candidate DUR-928 for alcohol-associated hepatitis. CEO James E. Brown will highlight positive Phase 2a results and provide details on the ongoing Phase 2b study with 300 hospitalized patients. DUR-928 acts as an epigenetic regulator, targeting DNA methylation to potentially improve cell survival and reduce inflammation in liver diseases. The presentation will be available on DURECT's website post-conference.
DURECT Corporation (Nasdaq: DRRX) presented new clinical data for DUR-928 at the 2021 International Liver Conference, showcasing potential efficacy in treating non-alcoholic steatohepatitis (NASH) and safety in subjects with hepatic impairment. The Phase 1b trial indicated a median 20% reduction in insulin resistance after 4 weeks of treatment. No adverse events were reported in the Phase 1 trial for hepatic impairment. DURECT is progressing with new trials and exploring additional applications for DUR-928.
DURECT Corporation (Nasdaq: DRRX) announced its participation at the International Liver Conference (EASL) from June 23-26, 2021, presenting two posters on DUR-928. The first poster highlights new efficacy signals from a Phase 1b study in nonalcoholic steatohepatitis (NASH) patients, showing improvements in liver health metrics. The second poster discusses a Phase 1 study on the safety and pharmacokinetics of DUR-928 in patients with varying hepatic impairments. Copies of the posters will be available on DURECT's website post-conference.
FAQ
What is the current stock price of Durect (DRRX)?
What is the market cap of Durect (DRRX)?
What is DURECT Corporation's primary focus?
What are DURECT's key products?
What is larsucosterol?
Has larsucosterol received any special designations from the FDA?
What is POSIMIR®?
Who distributes POSIMIR® in the United States?
What are ALZET® osmotic pumps?
What recent financial updates has DURECT provided?
How does DURECT engage with the scientific community?
Where can I find more information about DURECT Corporation?
